138 related articles for article (PubMed ID: 24941833)
21. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Barbee MS; Harvey RD; Lonial S; Kaufman JL; Wilson NM; McKibbin T; Hutcherson DA; Surati M; Valla K; Shah KS
Ann Pharmacother; 2013 Sep; 47(9):1136-42. PubMed ID: 24259728
[TBL] [Abstract][Full Text] [Related]
22. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Arnulf B; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; van de Velde H; Feng H; Cakana A; Deraedt W; Moreau P
Haematologica; 2012 Dec; 97(12):1925-8. PubMed ID: 22689676
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Moreau P; Karamanesht II; Domnikova N; Kyselyova MY; Vilchevska KV; Doronin VA; Schmidt A; Hulin C; Leleu X; Esseltine DL; Venkatakrishnan K; Skee D; Feng H; Girgis S; Cakana A; van de Velde H; Deraedt W; Facon T
Clin Pharmacokinet; 2012 Dec; 51(12):823-9. PubMed ID: 23018466
[TBL] [Abstract][Full Text] [Related]
25. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma].
Gu HT; Shu MM; Gao GX; Dong BX; Liang R; Yang L; Bai QX; Zhang T; Zhang YQ; Chen XQ
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):622-5. PubMed ID: 23906459
[TBL] [Abstract][Full Text] [Related]
27. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
28. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
29. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
[TBL] [Abstract][Full Text] [Related]
31. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
32. Induction therapy in multiple myeloma.
Harousseau JL
Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Algarotti A; Pascutto C; Lazzarino M
Eur J Haematol; 2009 Nov; 83(5):449-54. PubMed ID: 19519727
[TBL] [Abstract][Full Text] [Related]
34. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
35. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
Guo H; Zhou X; Jiang Y; Yang G; Sun C; Zhuang Y; Sun H; Lu M; Qian X; Chen F; Mao J; Chen H; Xia J; Shen Y
Am J Hematol; 2010 Jul; 85(7):499-501. PubMed ID: 20575036
[TBL] [Abstract][Full Text] [Related]
37. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M; Kedmi M; Duek A; Freidman T; Weiss M; Leiba R; Nagler A; Avigdor A
Br J Haematol; 2014 Sep; 166(5):702-10. PubMed ID: 24861981
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Lamm W; Drach-Schauer B; Eder S; Drach J
Oncology; 2013; 85(4):223-7. PubMed ID: 24080991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
